Live Breaking News & Updates on Concord biotech ipo

Stay updated with breaking news from Concord biotech ipo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Concord Biotech: US a key market, have strong presence in it: Ankur Vaid, Concord Biotech

So we expect to do better than what we have done historically, which was a CAGR growth of 18%. And this as economies of scale would kick in once a new site starts ramping up, we see our margin profiling being better than what it has been historically, which has been in the range of around 40%.

Indonesia , Kenya , Thailand , Mexico , China , Nepal , Ecuador , Singapore , India , Rare-enterprises , Ankur-vaid

Concord Biotech up 24% in debut, nets over $1 billion in valuation

India Business News: India's Concord Biotech saw a 24.6% surge in its share prices to Rs 923 on Friday. With the biopharma company's IPO initially priced at Rs 741 rupees,

Ahmedabad , Gujarat , India , China , Bengaluru , Karnataka , National-stock-exchange , Concord-biotech , National-stock , Business-news , Us-federal-reserve

concord biotech share price: Concord Biotech shares list at a healthy premium. What should investors do?

Concord Biotech is a biotechnology company and a leading maker of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022.

Japan , India , Anubhuti-mishra , Prashant-tapse , Quadria-capital-fund , Equity-research-analyst-at-swastika-investmart , Citigroup , Rakesh-jhunjhunwala-rare-enterprises , Concord-biotech , Equity-research-analyst , Mehta-equities , Rakesh-jhunjhunwala

Concord Biotech IPO allotment tomorrow: Latest GMP, here's how to check allotment status

Concord Biotech IPO allotment date is August 11. Check allotment status on Link Intime India Private Ltd's website. Refund process starts on August 14. Listing date is August 18 on NSE and BSE. GMP is +159.

India , Link-intime-india-private-ltd , Concord-biotech , Link-intime-india-private , Demat-account , Issue-type- , Concord-biotech-ipo , Concord-biotech-ipo-allotment-date , Concord-biotech-ipo-listing-date , Concord-biotech-ipo-allotment , Concord-biotech-ipo-allotment-status

Concord Biotech IPO: Issue subscribed nearly 6 times so far on last day; check GMP and other details

Analysts advised investors to subscribe to the issue given its complex product portfolio, presence in niche space, strong client relationship, and high entry barriers.

India , Japan , Apisf-apis , Citigroup , Helix-investment-holdings-pte-ltd , Concord-biotech , Quadria-capital , Mahindra-capital , Jefferies-india , Link-intime-india , Concord-biotech-ipo , Concord-biotech-ipo-day-3

Rakesh Jhunjhunwala's Concord Biotech IPO closes today, GMP, price band other details here

Concord Biotech shares are in very high demand during the ongoing share sale as the IPO was subscribed 3.72 times.

Japan , Indonesia , Paraguay , Mexico , Nepal , India , Ecuador , Kenya , Singapore , Thailand , Rakesh-jhunjhunwala , Motilal-oswal

Concord Biotech IPO final day to apply today: GMP update, subscription status

Concord Biotech IPO subscribed 10.96 times, with grey market premium at ₹202. Allotment likely on August 11, listing on August 18.

Singapore , Hindustan , India-general- , India , Abu-dhabi , Abuz-aby , United-arab-emirates , Rekha-jhunjhunwala , Rakesh-jhunjhunwala , Abu-dhabi-investment-authority , Concord-biotech